Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Devonian Health Group begins phase IIa study of Thykamine in atopic dermatitis

Nov. 13, 2017

KB-103 granted orphan drug designation by the FDA

Nov. 8, 2017

AnaptysBio reports topline phase I results for ANB-019

Nov. 7, 2017

Krystal Biotech receives equity-based award to support epidermolysis bullosa work

Nov. 7, 2017

Enrollment begins in phase I study of Samumed's SM-04755

Nov. 3, 2017

NeoMatrix Therapeutics to begin clinical testing of NMT-cP12

Nov. 3, 2017

Risankizumab meets all co-primary endpoints in pivotal phase III psoriasis studies

Oct. 27, 2017

Brickell Biotech reports results of confirmatory phase IIb study of sofpironium bromide

Oct. 25, 2017

Corbus Pharmaceuticals reports positive results from phase II study of anabasum in dermatomyositis

Oct. 20, 2017

AOBiome reports positive results from phase IIb study of AOB candidate for acne

Oct. 20, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...